Security
HALO · HALOZYME THERAPEUTICS, INC.
HALONASDAQCommon stockCurrentCIK 1159036Updated Sep 24, 2026
Name history
HALOZYME THERAPEUTICS INC · through Jul 3, 2019GLOBAL YACHT SERVICES INC · through Mar 12, 2004
HALO price & chart
Loading TradingView…
NASDAQ:HALO on TradingView ↗About the company
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme’s commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
In the news
Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 News provided by Halozyme Therapeutics, Inc. Nov 05, 2025, 16:05 ET Share this article Share to X Share this article Share to X SAN DIEGO ↗
Recent filings
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 1.01, 2.03, 3.02, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
144 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 2,525,323,000Source | 2,063,477,000Source | 1,733,270,000Source | 1,841,511,000Source |
| Property, Plant and Equipment, NetUSD | 44,442,000Source | 40,864,000Source | 38,108,000Source | 35,101,000Source |
| GoodwillUSD | 580,360,000Source | 416,821,000Source | 416,821,000Source | 409,049,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 981,467,000Source | 401,830,000Source | 472,879,000Source | 546,652,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 133,820,000Source | 115,850,000Source | 118,370,000Source | 234,195,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 426,273,000Source | 288,204,000Source | — | 231,072,000Source |
| Inventory, NetUSD | 176,475,000Source | 141,860,000Source | 127,601,000Source | 100,123,000Source |
| Assets, CurrentUSD | 825,207,000Source | 1,085,340,000Source | 746,424,000Source | 739,013,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 64,639,000Source | 38,951,000Source | 48,613,000Source | 45,024,000Source |
| Operating Lease, Right-of-Use AssetUSD | 37,695,000Source | 34,171,000Source | 36,836,000Source | 40,469,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,476,509,000Source | 1,699,656,000Source | 1,649,462,000Source | — |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 118,000Source | 123,000Source | 127,000Source | 135,000Source |
| Retained Earnings (Accumulated Deficit)USD | 54,786,000Source | 359,869,000Source | 90,550,000Source | 143,217,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -18,092,000Source | 3,829,000Source | -9,278,000Source | -922,000Source |
| Stockholders' Equity Attributable to ParentUSD | 48,814,000Source | 363,821,000Source | 83,808,000Source | 169,798,000Source |
| Additional Paid in Capital, Common StockUSD | 12,002,000Source | 0Source | 2,409,000Source | 27,368,000Source |
| Liabilities and EquityUSD | 2,525,323,000Source | 2,063,477,000Source | 1,733,270,000Source | 1,841,511,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 177,092,000Source | 139,100,000Source | 112,494,000Source | 130,789,000Source |
| Accounts Payable, CurrentUSD | 20,899,000Source | 10,249,000Source | 11,816,000Source | 17,693,000Source |
| Deferred Income Tax Liabilities, NetUSD | 42,924,000Source | — | — | — |
| Other Liabilities, NoncurrentUSD | 113,863,000Source | 54,758,000Source | 37,720,000Source | 30,433,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 156,193,000Source | 128,851,000Source | 100,678,000Source | 96,516,000Source |
| Deferred Tax Liabilities, NetUSD | 42,924,000Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 2,142,630,000Source | 1,505,798,000Source | 1,499,248,000Source | 1,492,766,000Source |
| Long-term Debt, Current MaturitiesUSD | 0Source | 0Source | 0Source | 13,334,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 2,142,630,000Source | 1,505,798,000Source | 1,499,248,000Source | 1,492,766,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 11,389,000Source | 10,263,000Source | 11,083,000Source | 6,493,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 51,565,000Source | 43,385,000Source | 36,620,000Source | 24,397,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 128,063,000Source | 74,245,000Source | 3,339,000Source | 83,941,000Source |
| Increase (Decrease) in InventoriesUSD | -2,554,000Source | 67,381,000Source | 26,884,000Source | 17,481,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 651,558,000Source | 479,064,000Source | 388,571,000Source | 240,110,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 725,965,000Source | 0Source | 0Source | 999,120,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -545,813,000Source | -262,723,000Source | -96,909,000Source | -487,005,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 6,970,000Source | 10,696,000Source | 15,294,000Source | 4,810,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 342,372,000Source | 250,000,000Source | 402,383,000Source | 200,002,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -85,174,000Source | -218,861,000Source | -407,987,000Source | 362,371,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 20,571,000Source | -2,520,000Source | -116,325,000Source | 115,476,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 136,421,000Source | 115,850,000Source | 118,370,000Source | 234,695,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 11,429,000Source | 10,565,000Source | 11,410,000Source | 6,107,000Source |
| Income Taxes Paid, NetUSD | 134,641,000Source | 80,618,000Source | 31,756,000Source | 16,224,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 51,565,000Source | 43,385,000Source | 36,620,000Source | 24,397,000Source |
| Amortization of Intangible AssetsUSD | 76,662,000Source | 71,049,000Source | 73,773,000Source | 43,148,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 171,000Source | 7,000Source | 0Source | -1,727,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -2,621,000Source | -1,529,000Source | -611,000Source | -129,000Source |
| GoodwillUSD | 580,360,000Source | 416,821,000Source | 416,821,000Source | 409,049,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 48,700,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 149,986,000Source | 113,041,000Source | 66,735,000Source | 46,789,000Source |
| Induced Conversion of Convertible Debt ExpenseUSD | 5,477,000Source | 0Source | 0Source | 2,712,000Source |
| InterestExpenseNonoperatingUSD | 18,126,000Source | 18,095,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 316,889,000Source | 444,091,000Source | 281,594,000Source | 202,129,000Source |
| Operating Lease, ExpenseUSD | 9,400,000Source | 8,600,000Source | 9,300,000Source | 3,300,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | 0Source |
| Other Nonoperating Income (Expense)USD | 21,472,000Source | 23,752,000Source | 16,317,000Source | 1,046,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 1,396,611,000Source | 1,015,324,000Source | 829,253,000Source | 660,116,000Source |
| Cost of RevenueUSD | 228,774,000Source | 159,417,000Source | 192,361,000Source | 139,304,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 207,092,000Source | 154,335,000Source | 149,182,000Source | 143,526,000Source |
| Operating Income (Loss)USD | 469,006,000Source | 551,475,000Source | 337,574,000Source | 267,531,000Source |
| Other Nonoperating Income (Expense)USD | 21,472,000Source | 23,752,000Source | 16,317,000Source | 1,046,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 466,875,000Source | 557,132,000Source | 348,329,000Source | 248,918,000Source |
| Income Tax Expense (Benefit)USD | 149,986,000Source | 113,041,000Source | 66,735,000Source | 46,789,000Source |
| Net Income (Loss) Attributable to ParentUSD | 316,889,000Source | 444,091,000Source | 281,594,000Source | 202,129,000Source |
| Earnings Per Share, BasicUSD per share | 2.64Source | 3.5Source | 2.13Source | 1.48Source |
| Earnings Per Share, DilutedUSD per share | 2.56Source | 3.43Source | 2.1Source | 1.44Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 119,840,000Source | 126,827,000Source | 131,927,000Source | 136,844,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 123,904,000Source | 129,424,000Source | 134,197,000Source | 140,608,000Source |
| Interest Expense (non-operating)USD | 18,126,000Source | 18,095,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 76,662,000Source | 71,049,000Source | 73,773,000Source | 43,148,000Source |
| Costs and ExpensesUSD | 927,605,000Source | 463,849,000Source | 491,679,000Source | 392,585,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 467,527,000Source | 557,852,000Source | 348,828,000Source | 248,918,000Source |
| Interest ExpenseUSD | — | — | 18,762,000Source | 16,947,000Source |
| Operating Lease, ExpenseUSD | 9,400,000Source | 8,600,000Source | 9,300,000Source | 3,300,000Source |
| Research and Development ExpenseUSD | — | 79,048,000Source | 76,363,000Source | 66,607,000Source |
Filing attachments
d148460dex41.htm · 8-K · 2026-09-22
Exhibit 4.1 Execution Version HALOZYME THERAPEUTICS, INC. and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee INDENTURE Dated as of September 22, 2026 1.50% Convertible Senior Notes due 2033 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction …
Read attachment ↗d945920dex41.htm · 8-K · 2025-11-12
EX-4.1 2 d945920dex41.htm EX-4.1 EX-4.1 EXHIBIT 4.1 HALOZYME THERAPEUTICS, INC. and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee INDENTURE Dated as of November 12, 2025 0% Convertible Senior Notes due 2031 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Const…
Read attachment ↗d945920dex43.htm · 8-K · 2025-11-12
EX-4.3 3 d945920dex43.htm EX-4.3 EX-4.3 EXHIBIT 4.3 HALOZYME THERAPEUTICS, INC. and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee INDENTURE Dated as of November 12, 2025 0.875% Convertible Senior Notes due 2032 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction …
Read attachment ↗d940775dex991.htm · 8-K · 2025-10-01
EX-99.1 2 d940775dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation Two of Ele…
Read attachment ↗